Harvard Bioscience Dirección
Dirección controles de criterios 1/4
El CEO de Harvard Bioscience's es Jim Green , nombrado en Jul 2019, tiene una permanencia de 4.75 años. compensación anual total es $2.39M, compuesta por 24.5% salario y 75.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.33% de las acciones de la empresa, por valor de $6.95M. La antigüedad media del equipo directivo y de la junta directiva es de 1.7 años y 6.5 años, respectivamente.
Información clave
Jim Green
Chief Executive Officer (CEO)
US$2.4m
Compensación total
| Porcentaje del salario del CEO | 24.5% |
| Permanencia del CEO | 4.8yrs |
| Participación del CEO | 4.3% |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 6.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued
May 04These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively
Apr 19Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)
Apr 04Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?
Mar 20What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?
Mar 07Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain
Feb 17An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued
Feb 02
Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?
Jan 15Harvard Bioscience: Wait For The Green Shoots Of Improvement
Jan 12When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?
Dec 28Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Dec 11At US$3.78, Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Worth Looking At Closely?
Nov 26Harvard Bioscience, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | US$2m | US$586k | -US$3m |
| Sep 30 2023 | n/a | n/a | -US$3m |
| Jun 30 2023 | n/a | n/a | -US$5m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$2m | US$574k | -US$10m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$4m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$3m | US$574k | -US$288k |
| Sep 30 2021 | n/a | n/a | -US$2m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | US$3m | US$574k | -US$8m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$3m | US$265k | -US$5m |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | US$432k |
| Mar 31 2019 | n/a | n/a | -US$819k |
| Dec 31 2018 | US$153k | n/a | -US$4m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$7m |
| Dec 31 2017 | US$129k | n/a | -US$2m |
Compensación vs. Mercado: La compensación total de Jim($USD2.39M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.60M).
Compensación vs. Ingresos: La compensación de Jim ha aumentado mientras la empresa no es rentable.
CEO
Jim Green (65 yo)
4.8yrs
Permanencia
US$2,392,240
Compensación
Mr. James W. Green, also known as Jim, has been the Chairman of Harvard Bioscience, Inc. since June 5, 2017 and its Director since April 30, 2015. He serves as President and Chief Executive Officer of Harv...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.8yrs | US$2.39m | 4.33% $ 6.3m | |
| CFO & Treasurer | 1.3yrs | US$571.27k | 0.097% $ 141.9k | |
| Senior Vice President of Operations | 1.8yrs | sin datos | sin datos | |
| Chief Legal Counsel & Corporation Secretary | 1.8yrs | sin datos | sin datos | |
| Senior Vice President of Global Sales | less than a year | sin datos | sin datos | |
| Vice President of Global People Operations | no data | sin datos | sin datos | |
| Director of Corporate Accounting & SEC Reporting | no data | sin datos | sin datos |
1.8yrs
Permanencia media
62yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de HBIO no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 9.1yrs | US$2.39m | 4.33% $ 6.3m | |
| Independent Director | 4.7yrs | US$213.09k | 0.47% $ 682.4k | |
| Lead Independent Director | 9.5yrs | US$223.06k | 1.08% $ 1.6m | |
| Independent Director | 6.6yrs | US$205.45k | 0.52% $ 754.5k | |
| Independent Director | 6.6yrs | US$198.09k | 0.55% $ 807.8k |
6.6yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de HBIO se considera experimentada (6.5 años de antigüedad promedio).